Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Lisa H LancasterBruno CrestaniPaul HernandezYoshikazu InoueDaniel WachtlinLazaro LoaizaManuel QuaresmaSusanne StowasserLuca RicheldiPublished in: BMJ open respiratory research (2019)
Based on pooled data from six clinical trials, the adverse event profile of nintedanib was manageable for most patients. Exploratory analyses based on extrapolation of survival data suggest that nintedanib extends life expectancy in patients with IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- clinical trial
- electronic health record
- interstitial lung disease
- big data
- end stage renal disease
- ejection fraction
- emergency department
- chronic kidney disease
- rheumatoid arthritis
- data analysis
- systemic sclerosis
- prognostic factors
- phase iii
- patient reported outcomes
- artificial intelligence
- open label
- double blind
- patient reported